Lymphoma

Lymphoma is a cancer of lymphocytes, the white blood cells at the centre of the immune system. The main kinds are B-lymphocytes, which make antibodies, T-lymphocytes, which help direct the immune response and destroy infected cells, and natural killer (NK) cells, which attack abnormal and virus-infected cells.

These cells travel through the lymphatic system, a network of vessels and small organs called lymph nodes found in places such as the neck, armpits, chest, abdomen and groin. The system returns fluid to the bloodstream, absorbs fat from the gut and filters out bacteria and viruses.

In lymphoma, one type of lymphocyte multiplies out of control inside the lymph nodes, making them swell. The abnormal cells can move to nearby nodes and to other lymphatic tissue such as the spleen, bone marrow, tonsils and thymus.

Signs and symptoms

The most typical sign is painless swelling of lymph nodes in the neck, armpits or groin, although enlarged nodes cannot always be seen or felt. Many people also have so-called B-symptoms: tiredness, fever, heavy night sweats, weight loss without trying and itching.

Swollen nodes in the chest can affect breathing, and nodes in the abdomen can cause discomfort there. Because symptoms are often mild or vague, and some people have none at all, lymphoma can be hard to recognise early.

Types

Lymphoma falls into two main groups: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

Hodgkin lymphoma arises from abnormal B-lymphocytes and is relatively rare. It is most common in young adults, with a second peak after the age of 55. Under the microscope it shows characteristic large cells called Reed-Sternberg cells. Infection with Epstein-Barr virus (EBV) or HIV raises the risk.

Non-Hodgkin lymphoma is a larger and more varied group, seen most often in older people. Around nine in ten cases start in B-lymphocytes and the rest in T-lymphocytes or NK cells. It often grows outside the lymph nodes as well, and is more common in people with HIV or a weakened immune system. The most frequent forms are diffuse large B-cell lymphoma and follicular lymphoma.

Staging

Staging describes where the lymphoma is and how far it has spread, which guides treatment and helps predict the outlook. Stage I involves one node or one group of neighbouring nodes; stage II, two or more groups on the same side of the diaphragm; stage III, nodes on both sides of the diaphragm along with the spleen; and stage IV, spread beyond the nodes to sites such as the bone marrow.

The main staging tool is a PET/CT scan after an injection of FDG, a radioactive form of glucose that cancer cells take up readily. Doctors also use a prognostic score (IPI) that counts age over 60, advanced stage, more than one site outside the nodes, a high blood LDH level and how much the illness limits daily activity.

Laboratory tests used in staging include a full blood count, liver and kidney function tests and, in some cases, a bone marrow biopsy.

Tests

Diagnosis rests on a lymph node biopsy, in which all or part of a node is removed and examined under the microscope for lymphoma cells, such as the Reed-Sternberg cells of Hodgkin lymphoma. Immunophenotyping and flow cytometry identify the cell type from markers on its surface (CD markers), and genetic tests look for chromosome changes, for example the t(14;18) translocation found in follicular lymphoma.

Blood tests help rule out other causes and set a baseline: a full blood count and blood film, urea and electrolytes for the kidneys, liver function tests, LDH, ALP and ESR, along with tests for HIV and hepatitis B and C. A high LDH, ALP or ESR, or a low albumin, can point to a less favourable outlook. A bone marrow biopsy shows whether the marrow is involved, although PET/CT often makes it unnecessary.

Imaging such as ultrasound, PET/CT, chest X-ray and MRI helps locate the disease and follow it over time.

Treatment

Treatment depends on the type of lymphoma, how fast it is growing and the person's age and general health. A slow-growing lymphoma that causes no symptoms may simply be watched with regular check-ups, with treatment started only if it progresses.

For both Hodgkin and non-Hodgkin lymphoma the standard approach is chemotherapy, often combined with radiotherapy. The drug regimen and number of cycles depend on stage and subtype. Because radiation carries risks such as later cancers, a PET/CT scan after chemotherapy is used to decide whether radiotherapy is needed.

Newer options include immunotherapy with antibodies that direct the immune system against lymphoma cells, such as nivolumab for classical Hodgkin lymphoma, and CAR-T therapy, in which the patient's own immune cells are modified to kill cancer cells. Some people receive a bone marrow or stem cell transplant.

Classification systems

Non-Hodgkin lymphomas have been grouped under several classification systems over the years, including an older working formulation from the National Cancer Institute (NCI), the REAL classification and the current World Health Organization (WHO) system.

These systems describe the diseases differently, so they do not line up one-to-one, and the same lymphoma may be known by more than one name. The WHO system separates B-cell lymphomas from T-cell and NK-cell lymphomas and includes forms such as follicular, mantle cell, Burkitt and diffuse large B-cell lymphoma.